| 来源类型 | Working Paper
|
| 规范类型 | 报告
|
| DOI | 10.3386/w24095
|
| 来源ID | Working Paper 24095
|
| Cost Sharing in Insurance Coverage for Precision Medicine |
| Mark V. Pauly
|
| 发表日期 | 2017-12-11
|
| 出版年 | 2017
|
| 语种 | 英语
|
| 摘要 | This paper describes current pattern of insurance coverage for precision medicines and, especially, companion diagnostics and explores what coverage would improve efficiency. We find that currently coverage is common for tests and treatments with clinical acceptance used at high volumes but is haphazard across both private insurers and Medicare for precision medicines in general. Analysis of the case of homogenous patient preferences finds that discovery and use of the test that converts an ordinary drug into a precision drug can either increase or decrease total spending, and might call for full or no coverage of test and treatments. Heterogeneity in marginal benefits from testing and treatment can call for partial coverage. Finally, varying threshold levels for diagnostic test results can lead to a demand curve to test and treatment that calls for partial cost sharing. Numerical examples and case studies of several test-treatment combinations illustrate these points. |
| 主题 | Health, Education, and Welfare
; Health
; Development and Growth
; Innovation and R&
; D
|
| URL | https://www.nber.org/papers/w24095
|
| 来源智库 | National Bureau of Economic Research (United States)
|
| 引用统计 |
|
| 资源类型 | 智库出版物
|
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/581767
|
推荐引用方式
GB/T 7714 |
Mark V. Pauly. Cost Sharing in Insurance Coverage for Precision Medicine. 2017.
|
|
文件名：
|
w24095.pdf
|
|
格式：
|
Adobe PDF
|
此文件暂不支持浏览
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
